BR0208887A - Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2 - Google Patents

Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2

Info

Publication number
BR0208887A
BR0208887A BR0208887-8A BR0208887A BR0208887A BR 0208887 A BR0208887 A BR 0208887A BR 0208887 A BR0208887 A BR 0208887A BR 0208887 A BR0208887 A BR 0208887A
Authority
BR
Brazil
Prior art keywords
diazepin
dihydro
mglur2
antagonists
benzo derivatives
Prior art date
Application number
BR0208887-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Geo Adam
Erwin Goetschi
Vincent Mutel
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0208887A publication Critical patent/BR0208887A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0208887-8A 2001-04-12 2002-04-02 Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2 BR0208887A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12
PCT/EP2002/003643 WO2002083665A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I

Publications (1)

Publication Number Publication Date
BR0208887A true BR0208887A (pt) 2004-06-29

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208887-8A BR0208887A (pt) 2001-04-12 2002-04-02 Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2

Country Status (37)

Country Link
US (1) US6548495B2 (cg-RX-API-DMAC7.html)
EP (1) EP1379522B1 (cg-RX-API-DMAC7.html)
JP (1) JP4043953B2 (cg-RX-API-DMAC7.html)
KR (1) KR100566178B1 (cg-RX-API-DMAC7.html)
CN (1) CN1268626C (cg-RX-API-DMAC7.html)
AR (1) AR035456A1 (cg-RX-API-DMAC7.html)
AT (1) ATE287883T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002310912B2 (cg-RX-API-DMAC7.html)
BG (1) BG108253A (cg-RX-API-DMAC7.html)
BR (1) BR0208887A (cg-RX-API-DMAC7.html)
CA (1) CA2441771C (cg-RX-API-DMAC7.html)
CZ (1) CZ20033002A3 (cg-RX-API-DMAC7.html)
DE (1) DE60202761T2 (cg-RX-API-DMAC7.html)
DK (1) DK1379522T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034796A (cg-RX-API-DMAC7.html)
ES (1) ES2235044T3 (cg-RX-API-DMAC7.html)
GT (1) GT200200072A (cg-RX-API-DMAC7.html)
HR (1) HRP20030791B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400991A3 (cg-RX-API-DMAC7.html)
IL (2) IL158021A0 (cg-RX-API-DMAC7.html)
JO (1) JO2273B1 (cg-RX-API-DMAC7.html)
MA (1) MA27011A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009317A (cg-RX-API-DMAC7.html)
MY (1) MY130369A (cg-RX-API-DMAC7.html)
NO (1) NO325300B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ528345A (cg-RX-API-DMAC7.html)
PA (1) PA8543201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20021072A1 (cg-RX-API-DMAC7.html)
PL (1) PL367086A1 (cg-RX-API-DMAC7.html)
PT (1) PT1379522E (cg-RX-API-DMAC7.html)
RU (1) RU2270197C2 (cg-RX-API-DMAC7.html)
SI (1) SI1379522T1 (cg-RX-API-DMAC7.html)
SK (1) SK13692003A3 (cg-RX-API-DMAC7.html)
UY (1) UY27259A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002083665A1 (cg-RX-API-DMAC7.html)
YU (1) YU79103A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307242B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
CN101056857B (zh) 2004-11-05 2010-12-01 弗·哈夫曼-拉罗切有限公司 异烟酸衍生物的制备方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR101151993B1 (ko) 2007-04-19 2012-06-01 에프. 호프만-라 로슈 아게 다이하이드로-벤조[b][1,4]다이아제핀-2-온 설폰아미드 유도체
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130424A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
EP2963043B1 (en) 2013-02-28 2018-05-30 Eisai R&D Management Co., Ltd. Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
RU2259360C2 (ru) * 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
NZ528345A (en) 2005-04-29
MY130369A (en) 2007-06-29
EP1379522B1 (en) 2005-01-26
CN1522252A (zh) 2004-08-18
BG108253A (bg) 2005-03-31
CA2441771A1 (en) 2002-10-24
MXPA03009317A (es) 2004-02-12
DE60202761D1 (de) 2005-03-03
DE60202761T2 (de) 2006-01-12
JP4043953B2 (ja) 2008-02-06
JO2273B1 (en) 2005-04-07
JP2004525965A (ja) 2004-08-26
PE20021072A1 (es) 2002-12-07
RU2270197C2 (ru) 2006-02-20
US6548495B2 (en) 2003-04-15
ZA200307242B (en) 2004-12-16
AR035456A1 (es) 2004-05-26
EP1379522A1 (en) 2004-01-14
CZ20033002A3 (cs) 2004-03-17
AU2002310912B2 (en) 2005-06-16
WO2002083665A1 (en) 2002-10-24
NO325300B1 (no) 2008-03-25
HRP20030791A2 (en) 2005-06-30
UY27259A1 (es) 2002-10-31
HK1068339A1 (en) 2005-04-29
MA27011A1 (fr) 2004-12-20
CA2441771C (en) 2008-12-30
PL367086A1 (en) 2005-02-21
YU79103A (sh) 2006-05-25
HRP20030791B1 (en) 2006-06-30
CN1268626C (zh) 2006-08-09
PA8543201A1 (es) 2002-10-31
ECSP034796A (es) 2003-12-01
KR100566178B1 (ko) 2006-03-29
SK13692003A3 (sk) 2004-05-04
ATE287883T1 (de) 2005-02-15
PT1379522E (pt) 2005-05-31
DK1379522T3 (da) 2005-05-30
NO20034496L (no) 2003-10-08
RU2003130648A (ru) 2005-04-10
US20020198197A1 (en) 2002-12-26
NO20034496D0 (no) 2003-10-08
GT200200072A (es) 2003-06-19
SI1379522T1 (en) 2005-04-30
IL158021A0 (en) 2004-03-28
KR20030088502A (ko) 2003-11-19
HUP0400991A3 (en) 2009-06-29
IL158021A (en) 2010-04-15
ES2235044T3 (es) 2005-07-01
HUP0400991A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
BR0208887A (pt) Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas i de mglur2
BR0208891A (pt) Derivados de dihidro-benzo[b]-[1,4]diazepin-2-ona como antagonistas de mglur2 ii
BR0307474A (pt) Derivados ii de diidrobenzodiazepin-ona
BR0108678A (pt) Novos compostos
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BR0209774A (pt) Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
BR0210616A (pt) Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0114635A (pt) Anticolinérgicos aplicáveis como medicamento bem como processo para a sua preparação
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0014326A (pt) Composto, medicamento, uso de compostos, e, processo para a preparação de compostos
BRPI0407387A (pt) Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento
BR0206935A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BR0015322A (pt) Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]